Introduction {#sec1-1}
============

Coronary heart disease (CHD) is characterized by atherosclerosis, which leads to vascular stenosis and occlusion. Dyslipidemia is known as a risk factor for CHD (1). Blood lipids have been reported to predict the risk of CHD (2, 3), which encouraged us to examine the association of lipid-related gene polymorphisms with CHD (4).

In this study, we selected seven adipocytokine signaling pathway genes, including three peroxisome proliferator-activated receptor (PPAR) signaling pathway genes \[angiopoietin-like 4 (*ANGPTL4*), adiponectin (*ADIPOQ*), and apolipoprotein A-V (APOA5)\], leptin (*LEP*), leptin receptor (*LEPR*), adiponectin receptor 1 (*ADIPOR1*), and 5'-AMP-activated protein kinase subunit gamma-1 (*PRKAG1*). PPAR or adipocytokine signaling pathway genes have been reported to be significantly upregulated in ruptured plaques (5). Of the remaining lipid-related genes, angiopoietin-like 3 (ANGPTL3) is a member of the angiopoietin-like protein family, which can regulate the activity of lipoprotein lipase in the lipolytic processing of triglyceride (TG)-rich lipoproteins (6). Apolipoprotein E (APOE) regulates plasma low-density lipoprotein (LDL) levels (7-9). Paraoxonase 2 (PON2) and paraoxonase 3 (PON3) are antioxidants against atherosclerosis (10). Very-low-density-lipoprotein receptor (VLDLR) can affect the metabolism of VLDL-TGs, which are associated with CHD (11). MLX-interacting protein-like (MLXIPL) gene encodes carbohydrate response element-binding protein that has been found to be significantly associated with CHD (12). Scavenger receptor class B type 1 (SCARB1) can regulate the levels of high-density lipoprotein cholesterol (HDL-C) and thus might influence CHD incidence (13). Cholesteryl ester transfer protein (CETP) has been shown to increase the risk of CHD by disrupting the balance of HDL-C and LDL-cholesterol levels in the plasma (14). Proprotein convertase subtilisin/kexin type 9 (PCSK9) can reduce blood cholesterol levels and is associated with CHD (15). Phosphatidic acid phosphatase type 2B (PPAP2B), which catalyzes phosphoric acid hydrolysis and thus contributes to glycerophospholipid and triacylglycerol syntheses, has been shown to be associated with CHD (16, 17).

On the basis of previous studies, the aim of this study was to assess the association of 17 lipid-related gene polymorphisms with CHD in the Han Chinese.

Methods {#sec1-2}
=======

Sample collection {#sec2-1}
-----------------

A total of 784 CHD cases and 739 non-CHD controls were enrolled in the current study. The enrolled cases were classified on the basis of the findings of standardized coronary angiography according to the Seldinger's method (18). The classification details have been reported in our previous studies (19-21). The study protocol was approved by the ethical committees of Ningbo First Hospital and Ningbo University. Written informed consent was obtained from all the participants.

Single nucleotide polymorphism (SNP) genotyping {#sec2-2}
-----------------------------------------------

DNA extraction and quantification were performed as previously described (22, 23). Genotyping was performed on the MassARRAY iPLEX^®^ assay platform (Sequenom, San Diego, CA, USA). The primer sequences and the details of the selected SNPs are presented in [Table 1](#T1){ref-type="table"}.

###### 

The primer sequences and the details of the selected SNPs[\*](#t1f1){ref-type="table-fn"}

  Gene SNP                                         Primer sequences
  ------------------------------------------------ -------------------------------------------------
  *PCSK9 rs2479409*                                1^st^\_ primer: ACGTTGGATGGTGCCTACCATAGAATTCTG;
  2^nd^\_primer: ACGTTGGATGGCCTACATGCATTTCAAGGG;   
  Extend primer: tTTCAGGTTTTAAGTTTGCAAAGA;         
  *PPAP2B rs72664392*                              1^st^\_primer: ACGTTGGATGCATTTATTGTCCACTGTGCC;
  2^nd^\_primer: ACGTTGGATGAAGGGCCTTCCCTTGTATCT;   
  Extend primer: tcTCTTCTATAGTGCCTAGCA;            
  *ANGPTL3 rs11207997*                             1^st^\_primer: ACGTTGGATGTATGTACTATAATTACCCC;
  2^nd^\_primer: ACGTTGGATGAAAAGCCGGCTCTAGCTGTC;   
  Extend primer: tcctCATGGATTAGTCTCCTCATCT;        
  *LEPR rs6656451*                                 1^st^\_primer: ACGTTGGATGCAATTACCATCAGCGCTGGG;
  2^nd^\_primer: ACGTTGGATGGAGAATGTCCACTACGCTTC;   
  Extend primer: TCATTCTTTCTCCCTTACC;              
  *ADIPOR1 rs7523903*                              1^st^\_primer: ACGTTGGATGTACAAAGTGCAGCTGGGAAG;
  2^nd^\_primer: ACGTTGGATGTGCCCAGGCTGTCAAAAATG;   
  Extend primer: GGTTGAGAAAGATTCAGAAAG;            
  *ADIPOQ rs266729*                                1^st^\_primer: ACGTTGGATGATGTGTGGCTTGCAAGAACC;
  2^nd^\_primer: CACGCTCATGTTTTGTTTTTGAAG;         
  Extend primer: CACGCTCATGTTTTGTTTTTGAAG;         
  *MLXIPL rs35493868*                              1^st^\_primer: ACGTTGGATGTCAAGCGATTCTCCCACTTC;
  2^nd^\_primer: ACGTTGGATGCCCTGTCTCTACCAAACATA;   
  Extend primer: GCATGTAGTCCTAGCTACT;              
  *PON3 rs11770903*                                1^st^\_primer: ACGTTGGATGAGGAAAAGACAGGAAACGGG;
  2^nd^\_primer: ACGTTGGATGCTAGAAGAAAGAGGGCCTAC;   
  Extend primer: caCTACCCTGCCAAGGAAA;              
  *PON2 rs12704796*                                1^st^\_primer: ACGTTGGATGTGAGAGCAGTCTGAGCTTTG;
  2^nd^\_primer: ACGTTGGATGTCCCCAGGCATGGGTATTG;    
  Extend primer: GAAGTCCCATACTCATGT;               
  *LEP rs13228377*                                 1^st^\_primer: ACGTTGGATGAAACCCATAACATAAAGCGG;
  2^nd^\_primer: ACGTTGGATGTTTGGGCATTACCAAACCCG;   
  Extend primer: atTGGCAGGCTCGGTTCACC;             
  *VLDLR rs7852409*                                1^st^\_primer: ACGTTGGATGGGCGACCGCTGGTTGGCTC;
  2^nd^\_primer: ACGTTGGATGCCCTGGATCAGGAAATTAGG;   
  Extend primer: gggtAAATTAGGACAGGCACC;            
  *APOA5 rs10750097*                               1^st^\_primer: ACGTTGGATGGGATAGGCTATTTCAAGCAG;
  2^nd^\_primer: ACGTTGGATGCCTGACTCATTTCCAGTCTC;   
  Extend primer: CTGCCACATAAAACCAC;                
  *PRKAG1 rs2293446*                               1^st^\_primer: ACGTTGGATGCATGACCCTCGCCGTCAGC;
  2^nd^\_primer: ACGTTGGATGAGGCAAGGAACCCACCCTTC;   
  Extend primer: cacctCCCTCCCCCGGGTCCTC;           
  *SCARB1 rs59358115*                              1^st^\_primer: ACGTTGGATGTGTGCAGGGTGTATGGAGG;
  2^nd^\_primer: ACGTTGGATGACCTTCTAGACCCTCATCTC;   
  Extend primer: TCCCTGGAAGAAGCCCC;                
  *CETP rs4783961*                                 1^st^\_primer: ACGTTGGATGCTTTGGTATTGGAGCAGGTG;
  2^nd^\_primer: ACGTTGGATGGCCAAGGAAACATGAGTCGG;   
  Extend primer: GGTCCTGCCCTAGTCC;                 
  *ANGPTL4 rs4076317*                              1^st^\_primer: ACGTTGGATGGCCCGAGGACGGTTTTTATA;
  2^nd^\_primer: ACGTTGGATGACCCCGCCTCCAAGACTCCT;   
  Extend primer: aataCAAGACTCCTCCGCCCACTC;         
  *APOE rs7259620*                                 1^st^\_primer: ACGTTGGATGAATGAGTCCCAGTCTCTCCC;
  2^nd^\_primer: ACGTTGGATGTTTCAGAGGAGAAACCCGTG;   
  Extend primer: GGTTCAGCAGCAAGA;                  

*PCSK9* - proprotein convertase subtilisin/kexin type 9; *PPAP2B* - phosphatidic acid phosphatase type 2B; *ANGPTL3* - angiopoietin-like 3; *LEPR* - leptin receptor; *ADIPOR1* - adiponectin receptor 1; *ADIPOQ* - adiponectin; *MLXIPL* - *MLX*-interacting protein-like; *PON3* - paraoxonase 3; *PON2* - paraoxonase 2; *LEP* - leptin; *VLDLR* - very-low-density-lipoprotein receptor; *APOA5* - apolipoprotein A-V; *PRKAG1* - 5'-AMP-activated protein kinase subunit gamma-1; *SCARB1* - scavenger receptor class B type 1; *CETP* - cholesteryl ester transfer protein; *ANGPTL4* - angiopoietin-like 4; *APOE* - apolipoprotein E

Statistical analysis {#sec2-3}
--------------------

Genotype and allele distributions were compared between the two groups using the Chi-squared test. Differences were determined by odds ratios (ORs) and 95% confidence intervals (CIs). Hardy-Weinberg equilibrium (HWE) test was used to assess the consistency of genotypic distribution in the controls. A two-tailed p\<0.05 was considered significant. A power analysis was performed using the Power and Sample Size Calculation software (v3.1.2, Nashville, USA).

Results {#sec1-3}
=======

As shown in the [Table 2](#T2){ref-type="table"}, 17 SNPs were detected in the upstream regions of lipid-related genes. *LEPR* rs6656451 was located in the upstream region of a transcript isoform. Among the tested SNPs, *APOE* rs7259620 was significantly associated with CHD \[genotype p=0.042 (df=2), allele p=0.025 (df=1), OR (95% CI)=1.196 (1.023-1.398); recessive model (GG+GA versus AA) p=0.018, df=1, OR (95% CI)=1.54(1.07-2.21)\]. *PON2* rs12704796, *ADIPOQ* rs266729, *VLDLR* rs7852409, and *PPAP2B* rs72664392 were excluded from further analyses since their genotypic distributions did not meet HWE in the controls (data not shown). In addition, the association of the remaining 12 SNPs with CHD could not be evaluated in the total samples (p\>0.05).

###### 

Comparison of genotype and allele frequencies of genes between CHD cases and non-CHD controls[\*](#t2f1){ref-type="table-fn"}

  Gene (SNP, allele)            Genotype counts (Cases vs. Controls)   Genotype (χ^2^, *P*)   Allele (χ^2^, *P*)   OR (95% CI)
  ----------------------------- -------------------------------------- ---------------------- -------------------- ---------------------
  *APOE (rs7259620, G/A)*       406/322/55 vs. 353/308/77              6.353, 0.042           5.05, 0.025          1.196 (1.023-1.398)
  *CETP (rs4783961, G/A)*       467/281/29 vs. 452/240/39              N.S.                   N.S.                 N.S.
  *MLXIPL (rs35493868, G/C)*    579/168/10 vs. 587/135/7               N.S.                   N.S.                 N.S.
  *ADIPOR1 (rs7523903, G/C)*    474/277/25 vs. 448/250/33              N.S.                   N.S.                 N.S.
  *APOA5 (rs10750097, G/A)*     235/378/171 vs. 237/355/146            N.S.                   N.S.                 N.S.
  *PCSK9 (rs2479409, G/A)*      392/326/66 vs. 358/316/63              N.S.                   N.S.                 N.S.
  *SCARB1 (rs59358115, G/A)*    583/186/15 vs. 546/178/15              N.S.                   N.S.                 N.S.
  *PRKAG1 (rs2293446, G/A)*     270/362/144 vs. 279/331/121            N.S.                   N.S.                 N.S.
  *PON3 (rs11770903, A/G)*      541/218/24 vs. 525/197/16              N.S.                   N.S.                 N.S.
  *LEP (rs13228377, A/G)*       450/296/38 vs. 416/279/43              N.S.                   N.S.                 N.S.
  *ANGPTL4 (rs4076317, C/G)*    394/322/58 vs. 361/315/54              N.S.                   N.S.                 N.S.
  *LEPR (rs6656451, C/T)*       678/93/5 vs. 649/80/1                  N.S.                   N.S.                 N.S.
  *ANGPTL3 (rs11207997, C/T)*   445/291/37 vs. 443/244/41              N.S.                   N.S.                 N.S.
  *PON2 (rs12704796, G/A)*      305/366/113 vs. 249/388/101            HWD in controls        N.A.                 N.A.
  *ADIPOQ (rs266729, C/G)*      399/316/61 vs. 401/263/67              HWD in controls        N.A.                 N.A.
  *VLDLR (rs7852409, C/G)*      546/208/29 vs. 513/190/30              HWD in controls        N.A.                 N.A.
  *PPAP2B (rs72664392, T/C)*    583/188/11 vs. 567/150/21              HWD in controls        N.A.                 N.A.

*PCSK9* - proprotein convertase subtilisin/kexin type 9; *PPAP2B* - phosphatidic acid phosphatase type 2B; *ANGPTL3* - angiopoietin-like 3; *LEPR* - leptin receptor; *ADIPOR1* - adiponectin receptor 1; *ADIPOQ* - adiponectin; *MLXIPL* - MLX-interacting protein-like; *PON3* - paraoxonase 3; *PON2* - paraoxonase 2; *LEP* - leptin; *VLDLR* - very-low-density-lipoprotein receptor; *APOA5* - apolipoprotein A-V; *PRKAG1* - 5'-AMP-activated protein kinase subunit gamma-1; *SCARB1* - scavenger receptor class B type 1; *CETP* - cholesteryl ester transfer protein; *ANGPTL4* - angiopoietin-like 4; *APOE* - apolipoprotein E. Genotypic distributions of *PON2* rs12704796, *ADIPOQ* rs266729, *VLDLR* rs7852409, and *PPAP2B* rs72664392 did not meet HWE in the controls. N.S. - not significant; N.A. - not analyzed; HWD in controls: did not meet HWE in the controls; 95% CI - 95% confidence interval; OR - odds ratio. *APOE* (rs7259620, G/A) was significant in recessive model \[GG+GA vs. AA, χ^2^=5.57, *P*=0.018, OR (95% CI)=1.54(1.07-2.21)\].

Further, subgroup analyses by gender were performed. *PON2* rs12704796 and *ADIPOR1* rs7523903 were excluded from the analyses since they did not meet HWE in the male subgroup; *ADIPOQ* rs266729 and *ADIPOR1* rs7523903 were excluded since they did not meet HWE in the female subgroup. *APOE* rs7259620 was significantly associated with CHD only in males \[χ^2^=8.397, df=2, p=0.015 by genotype; χ^2^=5.190, df=1, p=0.023 by allele; χ^2^=19.3, df=1, p\<0.0001 by recessive model (GG + GA versus AA), [Table 3](#T3){ref-type="table"}\]. In addition, *PPAP2B* rs72664392 showed a genotype-level association with CHD in females (χ^2^=9.878, df=2, p=0.007, [Table 3](#T3){ref-type="table"}).

###### 

Comparison of genotype and allele frequencies of genes between CHD cases and non-CHD controls by gender

  Group        Gene (SNP, allele)            Genotype counts (Cases vs. Controls)   Genotype (χ^2^, *P*)   Allele (χ^2^, *P*)   OR (95% CI)
  ------------ ----------------------------- -------------------------------------- ---------------------- -------------------- ---------------------
  **Male**                                                                                                                      
               *APOE* (rs7259620, G/A)       283/217/37 vs. 199/171/51              8.397, 0.015           5.190, 0.023         1.258 (1.032-1.533)
               *CETP* (rs4783961, G/A)       322/195/17 vs. 252/144/23              N.S.                   N.S.                 N.S.
               *MLXIPL* (rs35493868, G/C)    410/113/9 vs. 345/70/3                 N.S.                   N.S.                 N.S.
               *APOA5* (rs10750097, G/A)     163/261/114 vs. 145/194/82             N.S.                   N.S.                 N.S.
               *PCSK9* (rs2479409, G/A)      273/227/38 vs. 207/173/40              N.S.                   N.S.                 N.S.
               *SCARB1* (rs59358115, G/A)    404/123/11 vs. 310/104/7               N.S.                   N.S.                 N.S.
               *PRKAG1* (rs2293446, G/A)     186/250/97 vs. 152/196/71              N.S.                   N.S.                 N.S.
               *PON3* (rs11770903, A/G)      374/148/15 vs. 298/114/9               N.S.                   N.S.                 N.S.
               *LEP* (rs13228377, A/G)       315/196/27 vs. 243/152/26              N.S.                   N.S.                 N.S.
               *ANGPTL4* (rs4076317, C/G)    259/234/39 vs. 218/171/29              N.S.                   N.S.                 N.S.
               *LEPR* (rs6656451, C/T)       463/67/3 vs. 372/45/1                  N.S.                   N.S.                 N.S.
               *ANGPTL3* (rs11207997, C/T)   311/196/24 vs. 253/138/26              N.S.                   N.S.                 N.S.
               *VLDLR* (rs7852409, C/G)      379/139/20 vs. 295/105/17              N.S.                   N.S.                 N.S.
               *PPAP2B* (rs72664392, T/C)    410/117/9 vs. 326/86/9                 N.S.                   N.S.                 N.S.
               *PON2* (rs12704796, G/A)      217/242/79 vs. 147/221/52              HWD in controls        N.A.                 N.A.
               *ADIPOQ* (rs266729, C/G)      261/226/46 vs. 227/155/37              N.S.                   N.S.                 N.S.
               *ADIPOR1* (rs7523903, C/G)    331/185/18 vs. 251/156/12              HWD in controls        N.A.                 N.A.
  **Female**                                                                                                                    
               *APOE* (rs7259620, G/A)       123/105/18 vs. 154/137/26              N.S.                   N.S.                 N.S.
               *CETP* (rs4783961, G/A)       145/86/12 vs. 200/96/16                N.S.                   N.S.                 N.S.
               *MLXIPL* (rs35493868, G/C)    187/55/1 vs. 242/65/4                  N.S.                   N.S.                 N.S.
               *APOA5* (rs10750097, G/A)     72/117/57 vs. 91/161/64                N.S.                   N.S.                 N.S.
               *PCSK9* (rs2479409, G/A)      119/99/28 vs. 151/143/23               N.S.                   N.S.                 N.S.
               *SCARB1* (rs59358115, G/A)    179/63/4 vs. 236/74/8                  N.S.                   N.S.                 N.S.
               *PRKAG1* (rs2293446, G/A)     84/112/47 vs. 127/135/50               N.S.                   N.S.                 N.S.
               *PON3* (rs11770903, A/G)      167/70/9 vs. 227/83/7                  N.S.                   N.S.                 N.S.
               *LEP* (rs13228377, A/G)       135/100/11 vs. 173/127/17              N.S.                   N.S.                 N.S.
               *ANGPTL4* (rs4076317, C/G)    1135/88/19 vs. 143/144/25              N.S.                   N.S.                 N.S.
               *LEPR* (rs6656451, C/T)       215/26/2 vs. 277/35/0                  N.S.                   N.S.                 N.S.
               *ANGPTL3* (rs11207997, C/T)   134/95/13 vs. 190/106/15               N.S.                   N.S.                 N.S.
               *VLDLR* (rs7852409, C/G)      167/69/9 vs. 218/85/13                 N.S.                   N.S.                 N.S.
               *PPAP2B* (rs72664392, T/C)    241/64/12 vs. 173/71/2                 9.878, 0.007           N.S.                 N.S.
               *PON2* (rs12704796, G/A)      88/124/34 vs. 102/167/49               N.S.                   N.S.                 N.S.
               *ADIPOQ* (rs266729, C/G)      138/90/15 vs. 174/108/30               HWD in controls        N.A.                 N.A.
               *ADIPOR1* (rs7523903, C/G)    143/92/7 vs. 197/94/21                 HWD in controls        N.A.                 N.A.

*\*PCSK9* - proprotein convertase subtilisin/kexin type 9; *PPAP2B* - phosphatidic acid phosphatase type 2B; *ANGPTL3* - angiopoietin-like 3; *LEPR* - leptin receptor; *ADIPOR1* - adiponectin receptor 1; *ADIPOQ* - adiponectin; *MLXIPL* - MLX-interacting protein-like; *PON3* - paraoxonase 3; *PON2* - paraoxonase 2; *LEP* - leptin; *VLDLR* - very-low-density-lipoprotein receptor; *APOA5* - apolipoprotein A-V; *PRKAG1* - 5'-AMP-activated protein kinase subunit gamma-1; *SCARB1* - scavenger receptor class B type 1; *CETP* - cholesteryl ester transfer protein; *ANGPTL4* - angiopoietin-like 4; *APOE* - apolipoprotein E. Genotypic distributions of *PON2* rs12704796 in males, *ADIPOQ* rs266729 in females, and *ADIPOR1* rs7523903 did not meet HWE in the male controls, female controls, and both male and female controls, respectively. N.S. - not significant; N.A. - not analyzed; HWD in controls: did not meet HWE in the controls; 95% CI - 95% confidence interval; OR - odds ratio. *APOE* (rs7259620, G/A) was significant in males under recessive model \[GG+GA vs AA, χ^2^=19.3, *P*\<0.0001, OR (95% CI)=2.65 (1.69-4.15)\].

Age-based subgroup analyses revealed that *CETP* rs4783961, *MLXIPL* rs35493868, and *PON2* rs12704796 were significantly associated with CHD among participants younger than 55 years of age (*CETP* rs4783961: χ^2^=8.966, df=2, p=0.011 by genotype; *MLXIPL* rs35493868: χ^2^=4.870, p=0.027 by allele; χ^2^=4.88, df=1, p=0.027 by dominant model; *PON2* rs12704796: χ^2^=6.511, df=2, p=0.039 by genotype; χ^2^=6.210, df=1, p=0.013 by allele, χ^2^=5.03, df=1, p=0.025 by dominant model, [Table 4](#T4){ref-type="table"}). In addition, *LEPR* rs656451 was associated with CHD in participants older than 65 years of age (χ^2^=4.410, df=1, p=0.036 by allele, [Table 4](#T4){ref-type="table"}). No other SNPs were associated with CHD in the age-based subgroup analyses.

###### 

Comparison of genotype and allele frequencies of genes between CHD cases and non-CHD controls by age[\*](#t4f1){ref-type="table-fn"}

  Group       Gene (SNP, allele)            Genotype counts (Cases vs. Controls)   Genotype (χ^2^, *P*)   Allele (χ^2^, *P*)   OR (95% CI)
  ----------- ----------------------------- -------------------------------------- ---------------------- -------------------- ----------------------
  **≤55**                                                                                                                      
              *CETP* (rs4783961, G/A)       99/76/4 vs. 147/73/16                  8.966, 0.011           N.S.                 N.S.
              *APOA5* (rs10750097, G/A)     55/82/43 vs. 80/112/47                 N.S.                   N.S.                 N.S.
              *PCSK9* (rs2479409, G/A)      84/77/19 vs. 121/99/19                 N.S.                   N.S.                 N.S.
              *SCARB1* (rs59358115, G/A)    131/46/3 vs. 177/58/4                  N.S.                   N.S.                 N.S.
              *PRKAG1* (rs2293446, G/A)     64/78/37 vs. 88/109/39                 N.S.                   N.S.                 N.S.
              *PON3* (rs11770903, A/G)      129/45/5 vs. 173/58/8                  N.S.                   N.S.                 N.S.
              *MLXIPL* (rs35493868, G/C)    131/45/3 vs. 194/40/2                  N.S.                   4.87, 0.027          0.619 (0.403-0.951)
              *ADIPOR1* (rs7523903, G/C)    112/60/7 vs. 133/94/9                  N.S.                   N.S.                 N.S.
              *LEP* (rs13228377, A/G)       102/68/10 vs. 131/94/14                N.S.                   N.S.                 N.S.
              *VLDLR* (rs7852409, C/G)      116/53/11 vs. 165/61/11                N.S.                   N.S.                 N.S.
              *ANGPTL4* (rs4076317, C/G)    96/67/15 vs. 123/92/21                 N.S.                   N.S.                 N.S.
              *LEPR* (rs6656451, C/T)       149/29/0 vs. 213/22/1                  N.S.                   N.S.                 N.S.
              *ANGPTL3* (rs11207997, C/T)   94/73/11 vs. 144/81/11                 N.S.                   N.S.                 N.S.
              *PON2* (rs12704796, G/A)      74/86/20 vs. 73/124/42                 6.511, 0.039           6.210, 0.013         1.431 (1.079--1.879)
              *APOE* (rs7259620, G/A)       88/80/11 vs. 121/88/30                 HWD in controls        N.A.                 N.A.
              *ADIPOQ* (rs266729, C/G)      83/71/24 vs. 138/76/22                 HWD in controls        N.A.                 N.A.
              *PPAP2B* (rs72664392, T/C)    129/47/3 vs. 187/44/8                  HWD in controls        N.A.                 N.A.
  **55-65**                                                                                                                    
              *CETP* (rs4783961, G/A)       164/95/11 vs. 160/92/11                N.S.                   N.S.                 N.S.
              *APOA5* (rs10750097, G/A)     82/134/55 vs. 82/137/49                N.S.                   N.S.                 N.S.
              *PCSK9* (rs2479409, G/A)      139/118/14 vs. 122/123/23              N.S.                   N.S.                 N.S.
              *SCARB1* (rs59358115, G/A)    214/54/3 vs. 198/64/7                  N.S.                   N.S.                 N.S.
              *PRKAG1* (rs2293446, G/A)     91/126/53 vs. 94/126/44                N.S.                   N.S.                 N.S.
              *PON3* (rs11770903, A/G)      190/70/11 vs. 189/76/3                 N.S.                   N.S.                 N.S.
              *MLXIPL* (rs35493868, G/C)    222/44/3 vs. 214/46/2                  N.S.                   N.S.                 N.S.
              *ADIPOR1* (rs7523903, G/C)    169/92/9 vs. 171/82/10                 N.S.                   N.S.                 N.S.
              *LEP* (rs13228377, A/G)       156/96/19 vs. 147/106/15               N.S.                   N.S.                 N.S.
              *VLDLR* (rs7852409, C/G)      196/65/10 vs. 193/64/9                 N.S.                   N.S.                 N.S.
              *ANGPTL4* (rs4076317, C/G)    129/116/24 vs. 127/119/17              N.S.                   N.S.                 N.S.
              *LEPR* (rs6656451, C/T)       240/29/1 vs. 222/41/0                  N.S.                   N.S.                 N.S.
              *ANGPTL3* (rs11207997, C/T)   158/100/10 vs. 157/92/13               N.S.                   N.S.                 N.S.
              *PON2* (rs12704796, G/A)      97/130/44 vs. 88/144/37                HWD in controls        N.A.                 N.A.
              *APOE* (rs7259620, G/A)       140/106/25 vs. 125/112/31              N.S.                   N.S.                 N.S.
              *ADIPOQ* (rs266729, C/G)      138/115/17 vs. 151/88/24               HWD in controls        N.A.                 N.A.
              *PPAP2B* (rs72664392, T/C)    198/68/4 vs. 203/55/10                 HWD in controls        N.A.                 N.A.
  **≥65**                                                                                                                      
              *CETP* (rs4783961, G/A)       204/110/14 vs. 145/75/12               N.S.                   N.S.                 N.S.
              *APOA5* (rs10750097, G/A)     98/162/73 vs. 75/106/50                N.S.                   N.S.                 N.S.
              *PCSK9* (rs2479409, G/A)      169/131/33 vs. 115/94/21               N.S.                   N.S.                 N.S.
              *SCARB1* (rs59358115, G/A)    238/86/9 vs. 171/56/4                  N.S.                   N.S.                 N.S.
              *PRKAG1* (rs2293446, G/A)     115/158/54 vs. 97/96/38                N.S.                   N.S.                 N.S.
              *PON3* (rs11770903, A/G)      222/103/8 vs. 163/63/5                 N.S.                   N.S.                 N.S.
              *MLXIPL* (rs35493868, G/C)    244/79/4 vs. 179/49/3                  N.S.                   N.S.                 N.S.
              *ADIPOR1* (rs7523903, G/C)    193/125/9 vs. 144/74/14                N.S.                   N.S.                 N.S.
              *LEP* (rs13228377, A/G)       192/132/9 vs. 138/79/14                N.S.                   N.S.                 N.S.
              *VLDLR* (rs7852409, C/G)      234/90/8 vs. 155/65/10                 N.S.                   N.S.                 N.S.
              *ANGPTL4* (rs4076317, C/G)    169/139/19 vs. 111/104/16              N.S.                   N.S.                 N.S.
              *LEPR* (rs6656451, C/T)       289/35/4 vs. 214/17/0                  N.S.                   4.41, 0.036          0.545 (0.307-0.968)
              *ANGPTL3* (rs11207997, C/T)   193/118/16 vs. 142/71/17               N.S.                   N.S.                 N.S.
              *PON2* (rs12704796, G/A)      134/150/49 vs. 88/120/22               HWD in controls        N.A.                 N.A.
              *APO*E (rs7259620, G/A)       178/136/19 vs. 107/108/16              N.S.                   N.S.                 N.S.
              *ADIPO*Q (rs266729, C/G)      178/130/20 vs. 112/99/21               N.S.                   N.S.                 N.S.
              *PPAP2B* (rs72664392, T/C)    256/73/4 vs. 177/51/3                  N.S.                   N.S.                 N.S.

*PCSK9* - proprotein convertase subtilisin/kexin type 9; *PPAP2B* - phosphatidic acid phosphatase type 2B; *ANGPTL3* - angiopoietin-like 3; *LEPR* - leptin receptor; *ADIPOR1* - adiponectin receptor 1; *ADIPOQ* - adiponectin; *MLXIPL* - MLX-interacting protein-like; *PON3* - paraoxonase 3; *PON2* - paraoxonase 2; *LEP* - leptin; *VLDLR* - very-low-density-lipoprotein receptor; *APOA5* - apolipoprotein A-V; *PRKAG1* - 5'-AMP-activated protein kinase subunit gamma-1; *SCARB1* - scavenger receptor class B type 1; *CETP* - cholesteryl ester transfer protein; *ANGPTL4* - angiopoietin-like 4; *APOE* - apolipoprotein E. N.S. - not significant; N.A. - not analyzed; HWD in controls: did not meet HWE in the controls; 95% CI - 95% confidence interval; OR - odds ratio. *MLXIPL* (rs35493868, G/C) was significant in dominant model \[age ≤55 GG vs GC + CC, χ^2^=4.88, *P*=0.027, OR (95% CI)=0.59 (0.37--0.95)\]. *PON2* (rs12704796, G/A) was significant in dominant model \[age ≤55 GG vs GA + AA, χ^2^=5.03, *P*= 0.025, OR (95% CI)=1.59 (1.06--2.38)\]

Discussion {#sec1-4}
==========

In the present study, we examined the association of 17 lipid-related SNPs with CHD among 784 CHD cases and 739 non-CHD controls. We identified a male-specific association of *APOE* rs7259620 with CHD. Meanwhile, we also found a significant association of *PON2* rs12704796 with CHD among participants younger than 55 years of age. On the genotypic level, we identify a significant association of CHD with *PPAP2B* rs72664392 in females and *CETP* rs4783961 in participants younger than 55 years of age. On the allelic level, we identified a significant association of CHD with *MLXIPL* rs35493868 in participants younger than 55 years of age and *LEPR* rs6656451 in participants older than 65 years of age.

Previous studies have indicated that *APOE* is significantly associated with CHD. *APOE* ε*2* was shown to reduce the risk of CHD by 20% (24), whereas ε4 was shown to increase the risk of CHD by approximately 42% compared with ε3/ε3 genotype (25). Epidemiological evidence has shown that males are at a higher risk of CHD than females worldwide (26). Gender disparity has been found in APOE-related cardiovascular disease (27). In the previous studies, we have shown that CHD risk was gender-dependent in the Han Chinese and that *APOE* rs4420638 polymorphism was significantly associated with increased CHD risk in male Han Chinese (28). This observation might be explained by the differences of hormonal profiles, smoking status, alcohol-drinking, occupation, and dietary habits between males and females (29, 30). In the present study, we also identified a novel genetic variant of *APOE* associated with CHD in males.

PPAR2B is a negative regulator of inflammatory cytokines, leucocyte adhesion, cell survival, and migration in human primary aortic endothelial cells (31), suggesting that PPAR2B can protect blood vessel against inflammation (32). Mechanosensitive PPAP2B plays a critical role in promoting anti-inflammatory phenotype and maintaining the vascular integrity of endothelial monolayer under atheroprotective flow (33). However, discrepancies exist regarding the association of *PPAP2B* with CHD (34). *PPAP2B* rs1759752 is associated with increased CHD risk in males, while *PPAP2B* rs12566304 is associated with a decreased CHD risk in females (34). Other studies have shown that *PPAP2B* rs17114036-A is associated with CHD (35, 36). In contrast, *PPAP2B* rs17114036 is not associated with CHD after adjustments for gender (16, 35). Here, we identified a novel polymorphism (rs72664392) in *PPAP2B* promoter associated with CHD in females. This finding could be partly explained by the particular genetic background.

Aging is a pivotal risk factor for CHD (37, 38). The incidence of CHD in people younger than 40 years of age is 0.6%, and it increases two-fold or more with every 10-year increase in age (39). High adiponectin concentration has been shown to be associated with a lower risk of CHD in people younger 65 years of age (40). In people younger than 55 years of age, *PON2* rs12704796-A has been shown to increase the risk of CHD by 43.1%, whereas *MLXIPL* rs35493868-G has been shown to reduce the risk of CHD by 38.1%. In addition, *LEPR* rs6656451-T has been reported to reduce the risk of CHD by 45.5% among people older than 65 years of age.

Study limitations {#sec2-4}
-----------------

Our results did not demonstrate a significant association of 11 of the tested SNPs with CHD. A power analysis revealed that these SNPs showed a minimal or moderate power to detect a significant association in the current study (power=0.074-0.425). In addition, several SNPs did not present reliable association results in gender- and age-based subgroup analyses since their genotype distributions did not meet HWE in the controls. Future association study of these SNPs with CHD is warranted in other cohorts.

Conclusion {#sec1-5}
==========

Our study demonstrated the gender- or age-dependent association of six SNPs (*APOE* rs7259620, *PPAP2B* rs72664392, *CETP* rs4783961, *PON2* rs12704796, *MLXIPL* rs35493868, and *LEPR* rs6656451) CHD in Han Chinese population. However, future replication is required to validate our findings.
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